Veracyte (VCYT) Competitors $26.86 +0.17 (+0.64%) As of 01:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. GH, OPCH, RDNT, BTSG, SHC, SGRY, PRVA, CON, LFST, and ADUSShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), LifeStance Health Group (LFST), and Addus HomeCare (ADUS). These companies are all part of the "healthcare" industry. Veracyte vs. Its Competitors Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Privia Health Group Concentra Group Holdings Parent LifeStance Health Group Addus HomeCare Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Is GH or VCYT more profitable? Veracyte has a net margin of -2.18% compared to Guardant Health's net margin of -59.05%. Veracyte's return on equity of 3.02% beat Guardant Health's return on equity.Company Net Margins Return on Equity Return on Assets Guardant Health-59.05% -19,157.20% -25.96% Veracyte -2.18%3.02%2.80% Do insiders and institutionals have more ownership in GH or VCYT? 92.6% of Guardant Health shares are held by institutional investors. 6.1% of Guardant Health shares are held by company insiders. Comparatively, 1.4% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer GH or VCYT? Veracyte received 147 more outperform votes than Guardant Health when rated by MarketBeat users. Likewise, 73.02% of users gave Veracyte an outperform vote while only 71.76% of users gave Guardant Health an outperform vote. CompanyUnderperformOutperformGuardant HealthOutperform Votes30571.76% Underperform Votes12028.24% VeracyteOutperform Votes45273.02% Underperform Votes16726.98% Which has preferable earnings and valuation, GH or VCYT? Veracyte has lower revenue, but higher earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGuardant Health$774.00M8.03-$479.45M-$3.39-14.80Veracyte$463.39M4.53-$74.40M$0.4165.37 Does the media prefer GH or VCYT? In the previous week, Guardant Health had 11 more articles in the media than Veracyte. MarketBeat recorded 17 mentions for Guardant Health and 6 mentions for Veracyte. Veracyte's average media sentiment score of 1.01 beat Guardant Health's score of 0.63 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Guardant Health 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GH or VCYT? Guardant Health currently has a consensus price target of $53.29, indicating a potential upside of 6.22%. Veracyte has a consensus price target of $40.90, indicating a potential upside of 52.61%. Given Veracyte's higher probable upside, analysts clearly believe Veracyte is more favorable than Guardant Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Guardant Health 0 Sell rating(s) 0 Hold rating(s) 20 Buy rating(s) 1 Strong Buy rating(s) 3.05Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has more risk & volatility, GH or VCYT? Guardant Health has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. SummaryVeracyte beats Guardant Health on 10 of the 19 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.10B$3.12B$5.62B$8.58BDividend YieldN/A31.26%5.28%4.17%P/E Ratio-178.8314.2127.1919.81Price / Sales4.53179.01408.23154.60Price / Cash442.2957.5638.3234.64Price / Book1.874.796.994.65Net Income-$74.40M-$22.21M$3.23B$248.05M7 Day Performance-2.40%3.28%-0.18%-0.26%1 Month Performance-8.56%6.35%8.61%4.37%1 Year Performance22.99%16.34%32.26%13.65% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte3.9993 of 5 stars$26.86+0.6%$40.90+52.3%+20.9%$2.10B$463.39M-178.62790Positive NewsGHGuardant Health3.7973 of 5 stars$49.53+3.1%$53.29+7.6%+54.0%$6.14B$774.00M-13.911,790Gap DownOPCHOption Care Health3.9875 of 5 stars$31.67-0.7%$35.50+12.1%+13.2%$5.19B$5.19B26.615,600Positive NewsRDNTRadNet3.6922 of 5 stars$59.07+0.7%$69.75+18.1%-8.4%$4.43B$1.87B-843.748,970Positive NewsAnalyst ForecastBTSGBrightSpring Health Services0.7735 of 5 stars$23.86-1.0%$23.56-1.3%+99.3%$4.16B$11.86B-91.7735,000Gap UpSHCSotera Health3.4623 of 5 stars$12.36+0.5%$15.80+27.8%-2.0%$3.51B$1.11B49.443,000High Trading VolumeSGRYSurgery Partners2.7992 of 5 stars$23.36+0.7%$33.56+43.6%-13.3%$2.99B$3.17B-48.6712,200PRVAPrivia Health Group3.7288 of 5 stars$23.24+0.2%$27.77+19.5%+29.7%$2.83B$1.80B232.42810Positive NewsCONConcentra Group Holdings ParentN/A$22.09+0.3%$28.50+29.0%N/A$2.81B$1.93B16.4911,000Positive NewsLFSTLifeStance Health Group2.6166 of 5 stars$5.88+0.7%$8.50+44.6%-0.9%$2.29B$1.28B-22.626,640Positive NewsADUSAddus HomeCare4.7799 of 5 stars$116.56+3.0%$142.57+22.3%-3.7%$2.14B$1.21B26.6733,200Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Guardant Health Competitors Option Care Health Competitors RadNet Competitors BrightSpring Health Services Competitors Sotera Health Competitors Surgery Partners Competitors Privia Health Group Competitors Concentra Group Holdings Parent Competitors LifeStance Health Group Competitors Addus HomeCare Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VCYT Stock Free VCYT Stock Alerts